Related Experiment Video
Updated: Jan 4, 2026
12:00
Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
Published on: November 19, 2014
13.2K
Evidence for prefrontal cortex hypofunctioning in schizophrenia through somatosensory evoked potentials
Anastasios A Daskalakis1, Reza Zomorrodi1, Daniel M Blumberger2
1Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Schizophrenia Research
|October 31, 2019
Summary
Schizophrenia patients show altered somatosensory processing, specifically reduced N30 amplitude in the dorsolateral prefrontal cortex (DLPFC). This suggests local DLPFC dysfunction, not connectivity issues, impacting sensory processing in schizophrenia.
Area of Science:
- Neuroscience
- Psychiatry
- Somatosensory System
Background:
- Schizophrenia (SCZ) is associated with sensory processing deficits.
- Neural mechanisms of somatosensory impairments in SCZ remain unclear.
Purpose of the Study:
- To investigate somatosensory processing differences between SCZ patients and healthy controls (HC).
- To identify neural substrates of somatosensory alterations in SCZ.
Main Methods:
- Somatosensory evoked potentials (SEPs) generated via right median nerve stimulation.
- EEG recorded from 64 channels (10-20 montage) in 34 SCZ and 33 HC participants.
- Analysis focused on N30 (DLPFC) and N20 (S1) amplitudes.
Main Results:
- SCZ patients exhibited significantly smaller N30 amplitudes over the dorsolateral prefrontal cortex (DLPFC) compared to HC.
- N20 amplitudes in the somatosensory cortex (S1) were similar between groups.
- An association between N20 and N30 amplitudes was observed in SCZ, but not HC.
Conclusions:
- Somatosensory processing deficits in SCZ are linked to local DLPFC dysfunction.
- Findings suggest aberrant DLPFC activation rather than disrupted S1-DLPFC connectivity.
- Results may inform models of DLPFC hypofunctioning and identify therapeutic targets for SCZ.
